
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Economic analysis of availability of follow-on protein products : final report</dc:title>
  <dc:subject>Proteins -- economics</dc:subject>
  <dc:subject>Biological Products</dc:subject>
  <dc:subject>Drug Approval -- economics</dc:subject>
  <dc:description>The purpose of this report is to provide an unbiased estimate of potential cost savings from the introduction of FoPPs under multiple scenarios for abbreviated regulatory pathways. Findings from this analysis may be useful in the context of ongoing policy deliberations. A better understanding of the potential impact of legislative provisions for the regulatory pathway on cost savings may inform policymakers as such a pathway is considered.</dc:description>
  <dc:publisher>[Washington, DC] : Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, 2009</dc:publisher>
  <dc:contributor>United States. Department of Health and Human Services. Office of the Assistant Secretary for Planning and Evaluation.</dc:contributor>
  <dc:contributor>Lewin Group.</dc:contributor>
  <dc:contributor>i3 Innovus.</dc:contributor>
  <dc:format>Text</dc:format>
  <dc:format>Illustrations</dc:format>
  <dc:format>1 online resource (1 PDF file (various pagings))</dc:format>
  <dc:identifier>nlm:nlmuid-101615134-pdf</dc:identifier>
  <dc:identifier>101615134</dc:identifier>
  <dc:identifier>http://resource.nlm.nih.gov/101615134</dc:identifier>
  <dc:language>English</dc:language>
  <dc:coverage>United States</dc:coverage>
  <dc:rights>The National Library of Medicine believes this item to be in the public domain : https://creativecommons.org/publicdomain/mark/1.0/</dc:rights>
</oai_dc:dc>